1. Q4 2024 revenue rose 45% to $13.53 billion, fueled by Mounjaro and Zepbound growth. 2. Non-incretin revenue increased by 20% from Q4 2023, indicating strong overall performance.
The significant revenue increase is likely to positively influence LLY's stock price, similar to past quarters with strong sales growth.
Strong revenue performance can lead to increased analyst ratings and investor interest, which historically correlates with positive stock performance for LLY.
Sustained revenue growth may reflect ongoing market demand for LLY's products, promoting long-term investor confidence as observed in previous successful product launches.